Core Viewpoint - A class action securities lawsuit has been filed against Kyverna Therapeutics, Inc. due to alleged securities fraud related to its February 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased Kyverna common stock based on the company's offering documents from its IPO [2]. - The complaint alleges that the defendants made false statements and concealed critical information regarding the IPO strategy, terms, and disclosures in the offering documents [3]. - It is claimed that the underwriter defendants should have been aware of Kyverna's undisclosed issues and the misleading nature of the offering documents due to ongoing communications with the company's management [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Kyverna Therapeutics, Inc. during the relevant period have until February 7, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX